Document is current

Article History

Received: 4 November 2024

Accepted: 6 January 2025

First Online: 8 February 2025

Declarations

:

: GB reported small speaker fees from Bayer, Boehringer Ingelheim, Boston, Daiichi Sankyo, Microport, Janssen, and Sanofi outside of the submitted work. BF reported speaker fees and/or honoraria from BMS/Pfizer Alliance, and OMRON outside the submitted work. WFM reports speaker fees from iRhythm, consulting fees from Trimedics and Atricure, and research grants from Trimedics, all outside the submitted work. AJC reports personal fees for advising Acesion, Anthos, Incarda, Menarini, Milestone, Sanofi, Bayer, Daiichi Sankyo, Pfizer, Abbott, Biosense Webster, Biotronik, Boston Scientific, Medtronic, Johnson and Johnson outside the submitted work. RBS has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program under the grant agreement No 648131, from the European Union’s Horizon 2020 research and innovation program under the grant agreement No 847770 (AFFECT-EU), from the European Union’s Horizon Europe research and innovation program under the grant agreement ID: 101095480 and German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103 and 81Z0710114); German Ministry of Research and Education (BMBF 01ZX1408A) and ERACoSysMed3 (031L0239). Wolfgang Seefried project funding German Heart Foundation.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: For this type of study which was an anonymous survey among health care professionals, formal consent is not required.